Results 21 to 30 of about 6,454 (219)

Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management

Journal of Obesity & Metabolic Syndrome, 2023
The combination of glucagon-like peptide-1 (GLP-1) with other gut hormones including the glucose-dependent insulinotropic polypeptide (GIP) has been explored to complement and enhance further the GLP-1 effects on glycemia and weight loss.
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, Melanie J. Davies   +3 more
doaj   +1 more source

The Era for Dual and Triple Receptor Agonists Treating Type 2 Diabetes (T2D) [PDF]

, 2022
Recent trends for the treatment of type 2 diabetes (T2D) show dual or triple receptor agonists for incretins peptides. They are glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon (GCG).
185, 60228690, Bando, Hiroshi, バンドウ, ヒロシ, 板東, 浩   +4 more
core  

Blood pressure effects of SGLT2 inhibitors and GLP‐1 receptor agonists: Mechanisms, trial evidence and Real‐world data

British Journal of Clinical Pharmacology, EarlyView.
SGLT2 inhibitors and GLP‐1 receptor agonists modestly lower blood pressure across diverse patient populations, including those without diabetes. These effects appear largely independent of glycaemic control and offer additive value in high‐risk patients with overlapping comorbidities.
Andrej Belančić, Yusuf Ziya Sener, Marijana Vučković, Joseph Edgar Blais, Almir Fajkić, Emina Sher, Mislav Radić, Josipa Radić   +7 more
wiley   +1 more source

Pancreatic Safety of Tirzepatide and Its Effects on Islet Cell Function: A Systematic Review and Meta‐Analysis

Obesity Science & Practice
Background Endogenous glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) regulate islet cell function. GLP‐1 receptor agonists (GLP‐1RAs) have been associated with an elevated risk of acute pancreatitis.
A. B. M. Kamrul‐Hasan, Sunetra Mondal, Deep Dutta, Lakshmi Nagendra, Mohammed Ruhul Kabir, Joseph M. Pappachan   +5 more
doaj   +1 more source

Early Dose Escalation of Tirzepatide after Switching from Semaglutide in Type 2 Diabetes Mellitus [PDF]

Endocrinology and Metabolism
Tirzepatide has demonstrated greater efficacy than semaglutide in improving glycemic control and reducing body weight in patients with type 2 diabetes mellitus (T2DM).
Noboru Kurinami, Masafumi Takada, Seigo Sugiyama, Akira Yoshida, Kunio Hieshima, Tomoko Suzuki, Fumio Miyamoto, Keizo Kajiwara, Katsunori Jinnouchi, Kenji Ashida, Masatoshi Nomura, Hideaki Jinnouchi   +11 more
doaj   +1 more source

Maternal‐to‐Infant Transfer of Medications for Type 2 Diabetes Mellitus Via Breastmilk: A Systematic Review of Available Evidence and Clinical Guidelines

Clinical Pharmacology &Therapeutics, EarlyView.
This review evaluates the available pharmacokinetic data on the plasma‐to‐breastmilk transfer of first‐ and second‐line T2DM drugs against available clinical guideline recommendations. A list of drug therapies for treating T2DM was generated from national and international clinical guidelines.
Katherine Richardson, Joshua Kiptoo, Beatrice Mpora Odongkara, Francis Williams Ojara, Catriona Waitt   +4 more
wiley   +1 more source

Population pharmacokinetics of the GIP/GLP receptor agonist tirzepatide

CPT: Pharmacometrics & Systems Pharmacology
Tirzepatide is a first‐in‐class glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist approved as for the treatment of type 2 diabetes mellitus.
Karen Schneck, Shweta Urva
doaj   +1 more source

Utilization Trends of Dual GIP/GLP-1 Receptor Agonist, Newer Glucose-Lowering Medications, and Anti-Obesity Medications Among Patients With Chronic Kidney Disease With and Without Type 2 Diabetes

Kidney Medicine
Rationale & Objective: Tirzepatide, a dual GIP/GLP-1 receptor agonist, has been approved for type 2 diabetes (T2D) and obesity. However, the real-world utilization of tirzepatide remains unexplored, particularly in patients with chronic kidney ...
Panupong Hansrivijit, Janinne Ortega-Montiel, Deborah J. Wexler, Elisabetta Patorno, Julie M. Paik   +4 more
doaj   +1 more source

Bumps and humps in the success of Tirzepatide as the first GLP1 and GIP receptor agonist

Health Sciences Review, 2022
Glucagon-like peptide 1 (GLP-1) receptor agonists have acquired importance in Type 2 diabetes (T2D) treatment due to their glycemic advantages, cardiorenal effects, and favorable body weight. Despite this, the continuous discovery of higher effectiveness
Rouchan Ali, Sharma Arvind Virendra, Pooja A Chawla   +2 more
doaj   +1 more source

Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial [PDF]

BackgroundWeight reduction is a standard recommendation for obstructive sleep apnea (OSA) treatment in people with obesity or overweight; however, weight loss can be challenging to achieve and maintain without bariatric surgery.
Azarbarzin, Ali, Bednarik, Josef, Bunck, Mathijs C, Chakladar, Sujatro, Dunn, Julia P, Fietze, Ingo, Grunstein, Ron, Malhotra, Atul, Redline, Susan, Sands, Scott A, Schwab, Richard J, Weaver, Terri   +11 more
core   +1 more source